Provided by Tiger Trade Technology Pte. Ltd.

Jaguar Animal Health

0.7300
+0.100015.87%
Post-market: 0.7297-0.0003-0.04%17:49 EST
Volume:670.39K
Turnover:471.82K
Market Cap:3.05M
PE:-0.02
High:0.7399
Open:0.6100
Low:0.6097
Close:0.6300
52wk High:21.50
52wk Low:0.5600
Shares:4.18M
Float Shares:2.79M
Volume Ratio:3.82
T/O Rate:24.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-34.7371
EPS(LYR):-130.6878
ROE:-411.57%
ROA:-38.01%
PB:0.97
PE(LYR):-0.01

Loading ...

Jaguar Health announces one-time special stock dividend of Series O Convertible Preferred Stock with no dividend value disclosed

Reuters
·
Feb 18

First Berlin Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating

Reuters
·
Feb 12

Jaguar Health Reduces Debt Through Equity Exchange with Iliad

Reuters
·
Jan 26

Jaguar Health highlights strategic focus on rare disease development program

TIPRANKS
·
Jan 22

Jaguar Health to Present Rare Disease Pipeline at Sequire Investor Summit in Puerto Rico

Reuters
·
Jan 22

BRIEF-Jaguar Health Inc - Co & Unit Entered License Agreement With Woodward Specialty Llc - SEC Filing

Reuters
·
Jan 16

Jaguar Health Inc - Woodward Specialty to Pay Napo Upfront $18 Mln Including $16 Mln on Effective Date - SEC Filing

THOMSON REUTERS
·
Jan 16

Jaguar Health Signs $38 Million U.S. Licensing Deal With Future Pak for Crofelemer Products

Reuters
·
Jan 16

Jaguar Health to Present Updates at Lytham Partners Healthcare Investor Summit

Reuters
·
Jan 14

Jaguar Health Secures $350,000 Unsecured Loan from Accredited Investors

Reuters
·
Jan 13

Jaguar Health Signs $38 Million U.S. Licensing Deal with Future Pak for Mytesi and Canalevia-CA1

Reuters
·
Jan 12

Jaguar Animal Health Raises Short-Term Capital Through Notes

TIPRANKS
·
Jan 12

Jaguar Health Reports Crofelemer Reduces Parenteral Support in Pediatric Intestinal Failure Study

Reuters
·
Jan 06

Jaguar Health Secures $240,000 FDA Grant for Canalevia-CA1 Chemotherapy-Induced Diarrhea Study in Dogs

Reuters
·
Jan 02

Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome

Reuters
·
Dec 15, 2025

Jaguar Health Issues Pre-Funded Warrants in Exchange for Preferred Stock

Reuters
·
Dec 13, 2025

Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation

Reuters
·
Dec 11, 2025

Jaguar Health Inc. Held Special Meeting of Stockholders

Reuters
·
Dec 09, 2025

Jaguar Health Seeks EMA Feedback on Canalevia EU Approval for Dog Diarrhea

Reuters
·
Dec 02, 2025

Jaguar Health Secures Australian Patent for Crofelemer in Treating Short Bowel Syndrome and Related Disorders

Reuters
·
Nov 24, 2025